Streetbeat News

Revenues

MVST

Microvast targets a Q1 2024 revenue growth of 40%-60% YoY, with guidance of $65M-$75M, below the $132.84M estimate. The company aims for a gross margin of 20%-25%, plans to complete Clarksville Phase 1A with financing solutions, and secure long-term domestic customer contracts. It also reports new customer wins in APAC and EMEA, expanding its presence in the electrifying commercial vehicle markets.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 1:00 pm

SPY

The latest USA Redbook data shows a year-over-year increase of 5.2%, up from the previous 3.9%. This indicates a higher than expected growth in retail sales, which could signal a strengthening consumer spending trend.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:58 pm

SPY

The USA Redbook year-over-year data remains unchanged at 3.9%, indicating steady consumer spending patterns.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:57 pm

ONFO

Onfolio Holdings reported a Q4 2023 revenue of $1.27M, marking an increase from $1.12M in the same quarter the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:55 pm

BKTI

BK Technologies announced receiving two purchase orders from the USDA Forest Service for 5,620 BKR 5000 radios, as part of a five-year blanket purchase agreement initiated in May 2021. Since June 2021, the USFS has purchased over 22,000 BKR 5000 radios, transitioning from BK Technologies' KNG Portable Series.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:47 pm

VCNX

Vaccinex reported its FY23 earnings with an EPS of $(43.68), showing a significant improvement from last year's $(98.05). Revenue also increased to $570K from $275K YoY.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:44 pm

PAYX

Paychex, Inc. (PAYX) has projected its revenue growth for fiscal year 2024 to be between 5% and 6%. This forecast indicates a positive outlook for the company's financial performance in the upcoming year.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:40 pm

MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced that Canada's CADTH recommended public reimbursement for LIVMARLI for treating cholestatic pruritus in Alagille Syndrome patients. This follows Health Canada's authorization of LIVMARLI in 2023, marking it as the first and only approved medication for this condition in Canada. The recommendation is based on the ICONIC study's data, showing significant reductions in pruritus and serum bile acids. LIVMARLI is also approved in the U.S. and Europe for ALGS and PFIC.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:37 pm

LOBO

LOBO EV Technologies Ltd. (NASDAQ:LOBO) has announced a strategic collaboration with Serbian distributor CSM2017 Doo to expand its e-bicycle business in Serbia, marking a significant step in its Eastern European market expansion. The partnership focuses on the development and assembly of the CSM-01 e-bicycle model, with revenue generation expected to begin in Q2 2024. This move aligns with the growing demand for sustainable transportation in the region and leverages the growing European e-bicycle market, which is projected to reach $8.1 billion by 2030.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:34 pm

PAYX

Paychex reported Q3 adjusted EPS of $1.38, surpassing the $1.37 estimate, marking a 6.98% increase from last year. However, their sales of $1.44B fell short of the $1.46B estimate, a 4.20% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:31 pm